Canertinib is an irreversible tyrosine kinase inhibitor.It not only inhibits tyrosine phosphorylation but also enhances ubiquitinylation and accelerates endocytosis and subsequent intracellular destruction of ErbB-2 molecules. Canertinib alkylates a cysteine residue specific to ErbB receptors. The degradative pathway of ErbB receptor tyrosine kinases stimulated by tyrosine kinase inhibitors appears to be chaperone mediated, and thus is similar to the pathways activated by the heat shock protein 90 (Hsp90) antagonist geldanamycin and by stress-induced mechanisms.

Additional Information

Product #	C-2216
CAS #	289499-45-2
Formula	C24H25ClFN5O3 2HCl
MW	558.86
Appearance	Off-white to pale green Solid
Purity	99%
Solubility	DMSO (100 mg/ml)
Storage Temp	-20°C
Therapeutic Area	Oncological Disorders
Use	Canertinib is an irreversible EGFR tyrosine kinase inhibitor for the treatment of solid tumors

Additional Information

MDL Number	MFCD09837878
ChemACX	X1511904-1
InChI	InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)
SMILES	C=CC(=O)Nc1cc2c(cc1OCCCN3CCOCC3)ncnc2Nc4ccc(c(c4)Cl)F